Figure 1.

TEAEs over time: percentage of patients with TEAEs occurring in year 1 and newly occurring in years 2, 3, and 4 in ≥20% of patients with CP CML (both cohorts; any grade). ALT, alanine aminotransferase; CP CML, chronic phase chronic myeloid leukemia; TEAE, treatment-emergent adverse event. Denominators are the number of patients on treatment during the indicated years (note: the incidence of certain TEAEs appears higher in later years compared with previous years owing to a lower number of patients on treatment).